Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

420 with CNW — Health Insurance Premiums Lower in US Jurisdictions with Medical Marijuana

A recent International Journal of Drug Policy study has found that U.S. states with medical marijuana programs have seen major reductions in health insurance premiums. Compared to states without legal medical marijuana, the study observed that people in states with medical marijuana are paying lower insurance premiums.

Analysis of 10 years’ worth of National Association of Insurance Commissioners private health insurance data revealed that once a state legalized medical marijuana sales, health insurance premiums “dropped dramatically.”

Although the premium reductions were modest after the implementation of medical marijuana laws, yearly health insurance premiums in states with medical marijuana markets fell by $1,663 seven years after implementation, $1,542 eight years later, and $1,626 nine years later.

The researchers noted that although the reduction in health insurance premiums typically did not start until seven years after medical marijuana implementation, states with such programs eventually saw a “significant and sizable reduction” in premiums. The scientists specifically looked at individual private health plans instead of Medicaid or employee-sponsored insurance plans.

In addition, the research team only considered states with medical cannabis markets and excluded any analysis from states with both medical and recreational markets while using states without medical cannabis markets or those that hadn’t implemented already-passed medical cannabis policies as controls. Interestingly, the team found that states which adopted medical marijuana early have seen declines in private health insurance premiums from years three through nine after implementation while mid-adopting states saw an attenuated effect on health insurance premiums after the third year of implementation.

Furthermore, the researchers said that the nature of community rating and insurance pooling made it so that the savings derived from medical marijuana legalizations benefitted both marijuana users and nonusers. Alluding to cannabis reform critics who said legalizing cannabis could potentially result in an increase in healthcare costs, the researchers said that concerns about cannabis reform increasing the burden on healthcare were unfounded.

America’s state-legal cannabis industry now stretches across dozens of states and grants millions of Americans access to medical cannabis. Many people use cannabis as an alternative to pharmaceuticals to treat conditions such as chronic pain, anxiety, and insomnia.

Furthermore, medical marijuana programs allow patients with one or more of more than 20 qualifying conditions to use medical cannabis, often as an alternative to prescription medications. The list cancer, Alzheimer’s disease, anorexia, severe nausea, chronic pain, glaucoma, post-traumatic stress disorder (PTSD), muscle spasms, appetite loss, multiple sclerosis (MS) and HIV/AIDS.

This research depicting reductions in health insurance premiums is testament to the medical potential that marijuana possesses. It is therefore no wonder that companies are focused on developing FDA-grade pharmaceutical formulations from marijuana in order to treat different conditions, such as chronic pain.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Germans Hold Rally Calling for Cannabis Legalization

Demonstrations rocked the German capital city of Berlin last weekend as hundreds of Germans joined the country’s yearly marijuana legalization protests. Held just days before the German country met to discuss the fate of a draft measure that would get rid of Germany’s ban on cannabis, several hundred protestors joined the annual Hanfparade (Hemp Parade) and called on the government to legalize cannabis.

The rally began at the Berlin Rotes Rathaus (Red town hall) before the protestors walked a route that took them through the Unter den Linden boulevard and to the government district.

Held every year since 1997, the Hemp Parade’s main goal is to persuade the government to review and liberalize policies on soft drugs such as hashish and marijuana that come from the marijuana plant. Event organizers also support and advocate for expanded access to medical marijuana as well as the use of hemp, a plant in the cannabis family that produces very minimal amounts of the psychoactive compound tetrahydrocannabinol (THC).

This year’s demonstration motto was “Hemp is great for peace and climate.”

German lawmakers plan on legalizing marijuana and possibly allowing the possession of up to 25 grams of cannabis and home cultivation of up to three cannabis plants for adults. A proposed cannabis legalization law would also allow “cannabis clubs” to cultivate and sell cannabis to adults under specific rules. This includes limiting each customer to 50 grams of cannabis per month and using neutral packaging.

On top of generating millions of dollars in revenue, the proposed law would save Germany’s police force, the legal system and prison facilities more than $1.11 billion in operational costs every year.

Although reform activists hope the bill will advance and finally end cannabis prohibition in Germany, it will likely face plenty of pushback from associated agencies and organizations. For instance, the German Judges Association (DRB) claims upholding the measure will be difficult, calling it a “very small-scale law” that would require a very high degree of control and potentially lead to several court disputes. The DRB added that the legalization measure would have little effect on Germany’s illicit drug market.

German police have also criticized the proposed marijuana legalization measure. Like the DRB, the deputy head of the German Police Union (Gdp) says that the measure “lacks precision and oversight” and will burden the country’s police force to a significant degree. Gdp deputy federal chairman Alexander Poitz argued that the measure does not outline how to source and manage the additional personnel and technical effort law enforcement will need if it becomes law.

The Free Democratic Party (FDP) addiction and drug-policy spokesperson Kristine Lütke also said that the proposal in its current form would “create a bureaucratic monster.”

As more countries consider and implement marijuana legalization measures, many enterprises are likely to mushroom and thrive in the way that companies such as Advanced Container Technologies Inc. (OTC: ACTX) are finding success by doing business with marijuana companies in the U.S.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — DOJ Claims Appeals Court Wrongfully Ruled Ban on Cannabis Users’ Gun Rights as Unconstitutional

The Department of Justice (DOJ) is requesting a favorable result in related litigation and has alerted a federal court that it thinks a different court’s decision in a case involving cannabis and gun rights was made erroneously. The federal government wrote a one-page letter to the judges presiding over the Eleventh Circuit contesting a recent ruling by the Fifth Circuit Court, where it was concluded that the law forbidding individuals who consume cannabis from purchasing or owning firearms violates the Constitution.

The DOJ is vigorously appealing this judgment because it is relevant to litigation pending before the Eleventh Circuit. Although the focus of that lawsuit, which was originally brought by Nikki Fried, the former Agriculture Commissioner for Florida, is more restricted to patients registered with the state for medical cannabis to possess firearms, the case’s fundamental elements remain similar.

With the Florida-based lawsuit scheduled to engage in oral arguments next month, the DOJ has expressed concern that the recent ruling from the Fifth Circuit diverges from numerous other judicial decisions, both at the circuit and district court levels. Various courts have already heard cases challenging firearms prohibition at the federal level concerning marijuana consumers. While the ruling from the influential Fifth Circuit stands out, two separate district courts have reached the same conclusion.

The central argument revolves around a key precedent set by a recent Supreme Court decision that emphasized that any regulations on firearms must align with the historical setting established during the Second Amendment’s ratification in 1791. In its recent ruling, the Fifth Circuit dismissed the government’s position that gun restrictions placed on dangerous, mentally ill and actively intoxicated people in the 18th and 19th centuries complied with the strict standards established by Supreme Court precedent, noting that the government’s justification for the ban lacked a strong historical precedent.

At present, the decision made by the Fifth Circuit makes the ban invalid in Texas, Mississippi and Louisiana. Conversely, the Eleventh Circuit holds jurisdiction over Georgia, Florida and Alabama. Should the Eleventh Circuit ultimately affirm the ban’s constitutionality, it could potentially lead to Supreme Court intervention due to conflicting decisions among various circuit courts.

In an interesting twist, legal representatives for Hunter Biden, who has been accused of purchasing a gun in 2018 while disclosing that he was a crack cocaine user, have previously invoked a ruling from the Western District Court of Oklahoma. Biden is the son of President Joe Biden. Hunter’s legal team argues that the ruling, which found the ban on firearms for cannabis consumers to be unconstitutional, has similar bearings to their client’s case. The DOJ is currently appealing the district court’s decision to the Tenth Circuit Court.

Additionally, a judge in the Western District Court of Texas declared that laws that forbid the transfer and sale of firearms to marijuana users are unconstitutional.

Despite these recent legal developments, ATF remains steadfast in its stance that the prohibition of marijuana-related gun ownership is enforceable and unambiguous, even in places where marijuana use is allowed.

While the courts determine whether or not state-legal marijuana users can legally possess firearms, the formulations being developed can help patients steer clear of these controversies by taking the FDA-approved, cannabis-derived drugs.

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Marijuana Smell Sparks Smoking-in-Public Debate

As more states have legalized recreational cannabis use for adults aged 21 year and older, a debate on public consumption and marijuana’s distinct smell has grown increasingly fierce. Most, if not all states with recreational and medical cannabis programs have outlawed public consumption and require that eligible adults consume and cultivate cannabis in private residences away from the public eye.

However, marijuana smoke is a strong, pungent scent that can travel, especially when cannabis users are living in close quarters with other people, such as in apartments. This means that individuals abiding by state law and consuming cannabis in private often expose nonusers to smoke, albeit unintentionally, raising questions about where cannabis users could legally consume marijuana without affecting others.

Duluth, Minnesota, resident Carl Sack has taken a unique approach to cannabis smoke in public. Although Sack himself does not consume cannabis and actively states that he hates running into clouds of cannabis smoke in his neighborhood, he opposes local administrative efforts to outlaw public cannabis consumption. He is part of a group of residents who are calling on the Duluth City Council to reject a proposed measure that would ban consuming cannabis in the city’s parks.

Unlike other state cannabis measures, Minnesota’s recreational cannabis law did not ban public marijuana consumption outright, meaning per existing state laws, adults could smoke cannabis in most public outdoor places unless local governments specifically banned cannabis consumption.

Adults in New York can also smoke cannabis wherever tobacco is allowed if local governments allow it because the state treats cannabis as it does tobacco. However, users in other states have to smoke in private. In addition, state bans on public marijuana consumption are preventing states from taking advantage of a key demographic that could significantly improve their profits: cannabis tourists.

Some states are circumventing public consumption bans by legalizing cannabis consumption lounges, establishments that would provide a space for adults to consume cannabis “in public” without subjecting nonsmokers to pot smoke. On top of providing residents with a place to consume cannabis outside their houses legally, these establishments could allow states to tap into the cannabis tourism segment.

National Cannabis Industry Association chief executive officer Aaron Smith says that each state is approaching the issue of public consumption differently. He added that regulators should provide consumers with a legal way of consuming legal cannabis. Policymakers often talk about public safety during discussions regarding public marijuana consumption, stating that the public and especially children should not be exposed to marijuana’s pungent odor.

The specific ways that different jurisdictions adopt to address the issue of public smoking could impact various businesses that specialize in supplying indoor cultivation equipment, such as Advanced Container Technologies Inc. (OTC: ACTX). For example, if a proactive approach is taken and consumption lounges are permitted, more tourists or visitors can buy marijuana, which would in turn create additional demand for cultivators.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Affirms Product Superiority in Its 2023 Human Oral Nicotine Study, NIC-H22-1

Lexaria’s NIC-H22-1 study proved that its patented DehydraTECH(TM)-nicotine tobacco-free pouch was statistically significantly faster-acting than alternatives
The study, which involved 36 participants, embraced a randomized, double-blind, cross-over study design
It also affirmed Lexaria’s product superiority while also showing DehydraTECH’s potential

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released results from its 2023 human oral nicotine study NIC-H22-1. Of note was its patented DehydraTECH(TM)–nicotine tobacco-free pouch product superiority, particularly when pitted against world-leading brands ZYN(R) and on!(R). The study proved that Lexaria’s product was statistically significantly faster than the two alternatives in the median time required to reach comparable maximum nicotine concentrations (“Tmax”) levels (https://cnw.fm/17JMQ).

Lexaria’s CEO, Chris Bunka, lauded his team for this achievement, especially considering they had to work without as many resources as global multi-billion-dollar behemoths. He also lauded the company’s technology, citing its potential and advantages, as demonstrated in the study.

“This is a remarkable achievement that speaks to the capabilities of the DehydraTECH technology and also to the Lexaria R&D team, working ardently with scarce resources relative to global multi-billion-dollar behemoths,” he noted (https://cnw.fm/17JMQ).

Several intriguing data trends were observed from the study. For one, most of the subjects reported that they felt euphoric at all time points when they used Lexaria’s product. Lexaria also got the highest endorsement score, with statistical significance demonstrated at the second dosing visit. The highest percentage of users reporting that they considered the experience “pleasurable” at the 30-minute mark were also Lexaria users, and the company also scored best on the enjoyment scale.

Negative effects, meanwhile, such as nausea and severe hiccups were experienced more by the mass-market products than by the Lexaria formulation.

The study embraced a randomized, double-blind, cross-over study design involving 36 participants, all long-time heavy cigarette smokers who smoke at least ten cigarettes a day. Subjective effects, both positive and adverse, were assessed at baseline, 5 minutes, 30 minutes, and 120 minutes using a questionnaire to capture 25 different effects. All laboratory procedures for the study were conducted entirely by U.S.—based, third-party independent contract service providers (https://cnw.fm/17JMQ).

The results from this study not only validate Lexaria’s efforts but also affirm its product superiority while also showing DehydraTECH’s potential. This is a tremendous achievement for the company, given that this has been achieved in just five years. It reflects the company’s commitment to making the world a better place and its resolve to create value for its shareholders.

“We’ve always had an overwhelming determination and fierce conviction that we can make the world a better place and reduce the carnage caused by smoked cigarettes, and now we have human study data that demonstrates the advantages of DehydraTECH processed nicotine relative to the competitive landscape,” noted Mr. Bunka (https://cnw.fm/17JMQ).

For company information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Study Suggests Marijuana Users Are Less Predisposed to Type 2 Diabetes

A recently released analysis has found a link between a history of cannabis usage and a decreased incidence of type 2 diabetes in adulthood. The analysis was done on seven studies, which include four cohorts and 11 surveys, by researchers at Iran’s Tabriz University of Medical Sciences. Compiling the findings, NORML stated that the four cohorts combined totaled more than 478,000 participants.

The comprehensive analysis revealed that the chances of developing type 2 diabetes in those who had been exposed to marijuana were diminished by a factor of 0.48 compared to those without any marijuana exposure.

The researchers highlighted that the act of consuming cannabis could potentially confer a safeguarding impact on the likelihood of type 2 diabetes development. However, they appended that due to the notable variation in findings across studies, it would be prudent to encourage investigations of heightened credibility, given the surge in marijuana consumption and legalization.

The researchers elaborated, saying “to the best of our knowledge, our analysis constitutes the most current body of evidence concerning the connection between T2DM and marijuana use,” as cited by NORML. They continued: “Given the increasing popularity of marijuana usage and the legalization thereof, there exists a growing imperative to design prospective, long-term, randomized studies that delve into the genuine ramifications of marijuana consumption and furnish pragmatic guidelines for its management.”

Commonly referred to as adult-onset diabetes and type 2 diabetes mellitus, type 2 diabetes is a chronic ailment characterized by elevated blood sugar levels. This form of diabetes is more prevalent than type 1, and, as Harvard Medical School states, although it typically manifests in middle and later life, it is progressively affecting younger demographics.

The Centers for Disease Control and Prevention (CDC) report that more than 37 million Americans have diabetes, with type 2 diabetes comprising 90% to 95% of these cases. The CDC further noted that “insulin, a hormone manufactured by the pancreas, functions akin to a key, enabling blood sugar to enter the body’s cells and be utilized as energy. However, in cases of type 2 diabetes, cells exhibit an abnormal response to insulin, a phenomenon known as insulin resistance.”

The CDC further clarified: “The pancreas compensates by generating more insulin in an attempt to provoke a cellular response. With time, the pancreas becomes overwhelmed, leading to escalated blood sugar levels, consequently setting the stage for prediabetes and eventually type 2 diabetes.”

In 2020, a study examined the potential of marijuana to reduce diabetes risk in individuals with hepatitis C. The study’s authors reported that “HCV infection heightens the risk of insulin resistance, consequently increasing susceptibility to diabetes. In the general populace, indications suggest that marijuana usage might offer protective effects against diabetes and related disorders.”

Furthermore, NORML highlighted that previous observational inquiries uncovered an inverse relationship between marijuana use and the odds of adult-onset diabetes and obesity. In clinical trial settings, it was revealed that administering THCV improved glycemic control in type 2 diabetes cases.

The researchers added that a placebo-controlled trial, documented in February, reported substantial enhancements in cholesterol and blood sugar levels among diabetic subjects who consumed plant-derived cannabinoid extracts via an eight-week regimen of two daily CBD sublingual spray doses.

There are other medicinal attributes of marijuana which companies such as IGC Pharma Inc. (NYSE American: IGC) are looking to leverage in order to come up with FDA-approved formulations aimed at treating several conditions, including chronic pain.

NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Study Suggests Marijuana Users Are Less Predisposed to Type 2 Diabetes

The comprehensive analysis revealed that the chances of developing type 2 diabetes in those who had been exposed to…

420 with CNW — NAACP Reaffirms Support for Cannabis Legalization, Urges for Protection of Industry Employees

The National Association for the Advancement of Colored People (NAACP) has reaffirmed its support for cannabis reform at the federal level and is calling on cannabis industry regulators to protect employee rights in the sector. During its 114th National Convention in late July, the civil rights organization adopted a resolution renewing its support for federal cannabis legalization.

Although America is home to an incredibly lucrative state-legal cannabis industry that is spread across dozens of states, federal law still classifies marijuana as a Schedule I drug alongside narcotics like heroin and cocaine. While the industry has managed to grow into a global behemoth valued at billions of dollars, marijuana’s federal classification causes a myriad of issues for players in America’s marijuana sector.

These issues include limited access to banking services, capital and federal assistance even though the cannabis industry collectively generated more t han $15 billion in taxes last year alone. Federal prohibition also prevents marijuana businesses from accessing crucial financial services and forces them to operate on a cash-only basis, which significantly increases the risk of experiencing violent robberies.

NAACP also took a position on labor agreements on worker protections in the marijuana sector, stating that most people in the industry will be “workers rather than owners” and that employees throughout the cannabis supply chain have the right to a fair and safe workplace as well as a living wage. The civil rights organization noted that granting marijuana workers access to union representation, apprenticeship and training will ensure a wide pool of workers benefit from the lucrative cannabis industry.

Protecting employee rights in the cannabis sector will be especially beneficial for individuals from communities that were disproportionately affected by marijuana prohibition during the failed drug war. As it stands, the challenges presented by marijuana’s federal status make it much harder for social-equity applicants to survive, much less thrive, in the industry because they often lack the capital and connections needed to be successful in America’s overly bureaucratic cannabis sector.

According to the NAACP’s resolution, the organization supports descheduling cannabis and legalizing it at the federal level. The resolution also reaffirmed the association’s prior resolutions on marijuana, decriminalization, cannabis industries and equity in the sector. Furthermore, the NAACP expressed that it intended to advocate for cannabis measures that make labor peace agreements a condition for receiving licenses.

The civil rights organization adopted the measure without any discussion by members during the session.

The United Foods and Commercial Workers International Union (UFCW) praised the NAACP’s resolution and called it a crucial step toward ensuring legislators and employees understand just how profoundly a worker-friendly marijuana industry would benefit people of color.

If these calls for the federal legalization of marijuana are acted upon, new markets are set to open up for various companies such as Advanced Container Technologies Inc. (OTC: ACTX) as demand for marijuana could explode and those supplying cannabis companies with the products they need will benefit too.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Strategic Updates Concerning Patented DehydraTECH(TM) Technology

Lexaria’s human oral nicotine study, NIC-H22-1, comparing world-leading brands and the company’s DehydraTECH(TM)-Nicotine tobacco-free pouch, reported positive results, including higher pleasurable effects and reduced negative effects
A new patent has been granted to Lexaria and is strategically important to the company’s oral nicotine sector research and development efforts
Lexaria continues to research diabetes control and weight loss with its DehydraTECH(TM)-CBD, announcing favorable animal study results and the intent to develop a human clinical study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced updates regarding its patented DehydraTECH(TM) technology – which improves the way that active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. Lexaria’s primary focus for DehydraTECH research and development includes advancements of product candidates across key segments, including nicotine replacement, diabetes control and weight loss, and hypertension.

The company’s most recent announcement reported results from its 2023 human oral nicotine study NIC-H22-1, comparing Lexaria’s DehydraTECH(TM)-Nicotine tobacco-free pouch to world-leading brands ZYN(R) and on!. Using measurements to determine the median time required to reach comparable nicotine concentrations within the bloodstream (“Tmax”), Lexaria exhibited higher levels of certain pleasurable effects over the competition. DehydraTECH also provided the lowest frequency of unwanted negative effects, including moderate to severe nausea, demonstrating benefits from Lexaria’s formulation.

In addition to the announcement of favorable results from its NIC-H22-1 study, the company was recently granted a strategically important new patent in the oral nicotine sector by the United States Patent and Trademark Office, US Patent #11,700,875 Compositions and Methods for Sublingual Delivery of Nicotine. This new patent builds upon the company’s growing portfolio of 35 granted patents, with several more pending worldwide – spanning Lexaria’s research and development focus.

“We’ve always had an overwhelming determination and fierce conviction that we can make the world a better place and reduce the carnage caused by smoked cigarettes, and now we have human study data that demonstrates advantages of DehydraTECH processed nicotine relative to the competitive landscape,” said Chris Bunka, CEO of Lexaria (https://cnw.fm/8CwPl).

Separately, Lexaria also intends to conduct a human clinical study to examine its DehydraTECH-CBD formulation for diabetes control and weight loss. This intent comes after positive results were released in early August regarding its DIAB-A22-1 study in obese diabetic-conditioned animals, which achieved the following:

Lowered blood glucose levels by 19.9% (p<0.05)
Lowered overall body weight by 7% sustained over eight weeks
Witnessed a statistically significant increase in locomotor activity (p<0.05)
Lowered triglyceride levels by more than 25% (p<0.007)
Lowered blood urea nitrogen levels by 27.9% (p<0.001)

These successful pre-clinical results have the company determined to undertake a human study to investigate whether these improvements are also evidenced in humans. The study design is currently underway and will be submitted to an independent review board for approval.

As the company continues to grow and explore maximizing the potential of its DehydraTECH technology, a new wholly-owned subsidiary under the name Lexaria Nutraceutical Corp. (“LEXX Nutra”) has been formed. LEXX Nutra has been granted an exclusive, perpetual license entitling it to use DehydraTECH, or sublicense the use of DehydraTECH, to create consumer packaged goods and/or intermediate ingredients composed of any molecule except those associated with cannabis or nicotine. LEXX Nutra is also prohibited from using its licensing to manufacture any pharmaceutical product.

Lexaria Pharmaceutical Corp.’s licensing was also amended, ensuring it would only focus on manufacturing pharmaceutical products–excluding nicotine-associated molecules. The formation of Lexaria’s wholly-owned subsidiaries draws a distinct line in the sand for Lexaria, ensuring that proper research and development efforts for key indications are being diverted to the appropriate subsidiary.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — AMA Study Finds Marijuana Smoking Viewed as Safer Than Cigarette Smoking

According to a recent AMA study, people are beginning to perceive marijuana smoking or being around marijuana smoke as being less harmful than smoking or being around tobacco smoke. Researchers asked 5,035 American adults three times — in 2021, 2020 and 2017 — about their opinions of the hazards associated with both substances. They discovered a significant change over time, with more participants saying they thought marijuana smoke was typically safer than tobacco smoke.

Published in the “Journal of the American Medical Association” (JAMA) Substance Use and Addiction, the survey asked respondents whether they believed that smoking one joint of marijuana daily was significantly less safe than smoking one cigarette daily, significantly less safe, about the same amount of safety or much safer. The study authors noted that people believed using marijuana regularly to be safer than using tobacco. Moreover, this perception became progressively more favorable toward marijuana as the years went by.

For instance, 33.7% of respondents in 2017 indicated that smoking cannabis once a day was either substantially or slightly riskier than smoking a cigarette, compared to 36.6% who believed cannabis was safer. About 30% claimed that they posed similar hazards. Only 25.5% of people still held this belief in 2021, whereas 44.3% of people, a 21% rise from 2017, thought cannabis was less risky than cigarettes.

Similar patterns were seen when respondents were questioned about the relative risks of being exposed to cigarette and cannabis smoke. In 2017, 35.1% of respondents believed that exposure to cigarette smoke was more hazardous than exposure to secondhand marijuana smoking, while 29.2% disagreed. Another 35.6 percent disagreed, claiming that neither was less risky nor safer. In 2021, four years later, 25.5% of respondents claimed that marijuana smoke in close proximity to others was worse than cigarette smoke, while 40.1% disagreed.

Participants were also asked to rank the relative safety of tobacco smoke and marijuana smoke for various demographics. Among adults, 12.6% thought cannabis was mostly or entirely safe, compared to 2.4% who thought the same about tobacco. Compared to cigarettes, which had a response of 1.8%, cannabis had a response of 4.8% that it was entirely or somewhat safe for youngsters. And compared to cigarettes, cannabis smoke was deemed to be usually safe for pregnant women by 5.3% of respondents, versus 1.4% for cigarettes.

The authors noted that the legalization of cannabis in the participant’s state of residence was not a standalone predictor of change over time. This shows that the rising view of marijuana safety may be a more widespread, nationwide trend rather than a trend limited to places where cannabis use is allowed.

This finding appears to partially conflict with the authors’ prediction that if more states legalize cannabis, risk perception may decline even further, which may be related to increased cannabis intake and exposure to secondhand marijuana smoke.

The authors express concern about the shift in public perceptions regarding marijuana’s relative safety and suggest that public health initiatives may be required to inform the public about potential risks and stop the rising social acceptance of marijuana smoke exposure.

This new study’s release coincides with a recent Gallup poll revealing that almost one-half of Americans have tried marijuana and that more individuals currently smoke marijuana than tobacco cigarettes. The majority also expresses no particular concern about the consequences of adult marijuana use.

Given that many people use marijuana for medicinal purposes, one way to reduce any possible harms from smoking the substance is by switching to any FDA-approved cannabis medicines that manufacturers such as IGC Pharma Inc. (NYSE American: IGC) offer to address chronic pain and other symptoms.

NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.